



MHRA

10 South Colonnade Canary Wharf London E14 4PU United Kingdom

Our Ref:IVD000904

Dr Edward Wang Wellkang Ltd Suite B 29 Harley Street London W1G 9QR

27 March 2020

Dear Dr Wang

$\langle \! \rangle$

IN VITRO DIAGNOSTIC MEDICAL DEVICES REGULATIONS 2002: REGULATION 44 Registration of manufacturers of *In-Vitro Diagnostic* Medical Devices and devices for Performance Evaluation

Thank you for informing the Competent Authority of the change to the original notification dated (date the registration was registered); Manufacturers Names, Newscen Coast Bio-Pharmaceutical Co., Ltd. located at Manufacturers Address:- No.65, 6th Street, Tianjin TEDA, Tianjin, China 300457 for whom you are acting as the authorised representative and for supplying the medical device information.

The change(s) to your registration has been recorded based on your declaration that you have determined that the device(s) fall within the definition of "in vitro diagnostic medical device", and that you have classified it/them correctly taking into account the intended purpose(s) and mode(s) of action. In accepting your registration, I should make clear that the Competent Authority does not examine each individual notification and therefore cannot and does not necessarily endorse these determinations. Neither does this letter represent any form of accreditation or approval by the UK Competent Authority.

Your registration is based upon your declaration on the RG3 form and means that you should now be operating under the In Vitro Diagnostic Medical Devices Directive and the 2002 Regulations for the products you asked us to register, by fully complying with the essential requirements, CE marking those products or labelling them as such.

If you stop placing devices on the market or if you are not complying with the Regulations you should inform us as required by the Regulations. You should be aware that it is an offence to place on the market CE marked devices that do not comply with the Regulations.

The information you provided has been recorded against the reference number shown at the top of this letter, which we ask you to quote in all future correspondence and communications.

Please inform us of any changes to:

- the company information
- additional generic groups of devices or, for Annex II or Self-Test devices, additional devices
- discontinuation of a generic group of devices or, for Annex II or Self-Test devices, discontinuation of devices

Medicines & Healthcare products Regulatory Agency



Please use RG3, the Registration form, to tell us about any of these changes. A ee of £70 is payable for each change or set of changes notified.

Thank you for registering the following generic groups of devices

```
1. Part 5: IVDs which are not Annex II and not self-test devices
2.
3.
   For reagnets, reagent products, calibration and control materials:
4.
   group by common technological characteristics and/or analytes
5.
6.
   New products:
7.
        None
8.
   For performance evaluation:
9.
10.
        None
11.
12. Neither:
13.
        IC&II Hardware + accessories + consumables + softwa
14.
        C-Reactive Protein
15.
        Procalcitonin
16.
        Alphafetoprotein
17.
        Carcinoembryonic Antigen
        Cardiac Marker Controls
18.
19.
        D-Dimer Rapid Test
20.
        Albumin (IC)
        Thyroid Stimulating Hormone
21.
22.
        Coronavirus
23.
24.
25. For other IVDs, group by appropriate indications
26.
27. New products:
28.
        None
29.
30. For performance evaluation:
31.
        None
32.
33. Neither:
34.
        None
35.
36.
37. Part 6: IVDs which are Annex II or self-test devices
38.
39. For reagnets, reagent products, calibration and control materials:
40. group by common technological characteristics and/or analytes
41.
42. New products:
43.
        None
44.
45. For performance evaluation:
46.
        None
47.
48. Neither:
49.
        None
50.
51.
52. For other IVDs, group by appropriate indications
```

Medicines & Healthcare products Regulatory Agency 53. 54. New products: 55. None 56. 57. For performance evaluation:



53.
54. New products:
55. None
56.
57. For performance evaluation:
58. None
59.
60. Neither:
61. None
62.

If you have any queries regarding your registration, please do not hesitate to contact us.

Yours sincerely

Malcolm Ridgway Data Integrity Support Officer

